Daiichi picks former Novartis CMO John Tsai to head up R&D Read more →

Candel glows brighter with $100M RTW royalty deal to fund prostate cancer drug's launch Read more →

Novartis winds down ph. 1 solid tumor program after lacking efficacy Read more →